The Japanese Journal of Pharmcology

Jpn. J. Pharmacol. 85 Supplement I (2001)

The 74th Annual Meeting

March 21-23, 2001
Yokohama

Chairman: Tetsuo Oka

Abstracts

============================================================================================

Committee
Hitoshi Endou (Kyorin Univ. Sch. of Medicine)
Yoshio Goshima (Yokohama City Univ. Sch. of Medicine)
Keitaro Hashimoto (Yamanashi Medical Univ.)
Koichi Ishikawa (Nihon Univ. Sch. of Medicine)
Mitsuru Kawaguchi (Tokyo Dental Coll.)
Masahiro Kawamura (Jikei Univ. Sch. of Medicine)
Shinichi Kobayashi (St. Marianna Univ. Sch. of Medicine)
Kazuhiro Kohama (Gunma Univ. Sch. of Medicine)
Masataka Majima (Kitasato Univ. Sch. of Medicine)
Teruhiko Matsumiya (Tokyo Medical Univ.)
Masayoshi Mishina (Sch. of Medicine, Univ. of Tokyo)
Kazutaka Momose (Sch. of Pharmaceutical Sciences, Showa Univ.)
Takamura Muraki (Sch. of Medicine, Tokyo Women's Medical Univ.)
Toshio Nakaki (Teikyo Univ. Sch. of Medicine)
Ikuo Nishimoto (Keio Univ. Sch. of Medicine)
Yasuo Ogawa (Juntendo Univ. Sch. of Medicine)
Katsuji Oguchi (Sch. of Medicine, Showa Univ.)
Tsutomu Suzuki (Sch. of Pharmacy, Hoshi Univ.)
Toshimitsu Uchiyama (Toho Univ. Sch. of Medicine)
Hajime Yasuhara (Sch. of Medicine, Showa Univ.)

Secretariat
Hiroyuki Kobayashi
Department of Pharmacology, School of Medicine, Tokai University
Isehara 259-1193, JAPAN
Phone: +81-463-93-1121/ext.2560
Fax: +81-463-93-2896
E-mail: nenkai@m.med.u-tokai.ac.jp

Contents

Special Lectures

SL-1 Isolation and self-renewal of neural stem cells
Hideyuki Okano .......... 2P

SL-2 Pharmacology and animal experimentation
Tatsuji Nomura .......... 2P

SL-3 Frontiers of human genome project and implications to pharmacology
Nobuyoshi Shimizu .......... 2P

SL-4 Molecular mechanism of the death factor-induced apoptosis and its associated diseases
Shigekazu Nagata .......... 2P

SL-5 Current issues in clinical trials in Japan
Kiyoshi Kurokawa .......... 3P

SL-6 Brain drug targeting using gene technologies
William M. Pardridge .......... 3P

SL-7 A new pharmacological avenue to antidepressants
James H. Woods .......... 3P

SL-8 Calcium regulation of striated muscle contraction and its genetic disorder
Iwao Ohtsuki .......... 3P

SL-9 Studies on histamine with histidine decarboxylase as a probe: from purificaiton to gene knockout
Takehiko Watanabe .......... 4P

SL-10 Mouse models of colon cancer and treatment
Makoto Taketo .......... 4P

Award Lectures

AL-1 Functional alterations of astroglia on brain pathologies and their intracellular mechanisms
Yutaka Koyama .......... 5P

AL-2 LOX-1, the endothelial oxidized LDL receptor: identification and functional characterization
Tatsuya Sawamura .......... 5P

AL-3 Functional analysis of calcineurin-mediated signalling pathway using fission yeast as a model system
Reiko Sugiura .......... 5P

Symposia

S1 Drug design based on the structure-function of ion channels and transporters .......... 8P

S2 Physiological functions of neuropeptide PACAP .......... 9P

S3 NF-kB as a therapeutic durg target .......... 10P

S4 Functional analysis of mast cells by the real-time monitoring technique .......... 11P

S5 High throughput screening (HTS) of drugs .......... 13P

S6 Diversity of roles of endogenous prostaglandin E₂: from knockout mouse studies to drug design .......... 14P

S7 Pharmacology and physiology of perivascular nerves regulating vascular function ........... 16P

S8 Functional biology and model mice in the post-genome era .......... 17P

S9 Neuronal mechanisms to determine the fate: from development to death and survival .......... 18P

S10 Recent advances in cardiac regulatory mechanisms .......... 19P

S11 Molecular chaperones - biology to pharmacology - .......... 21P

S12 Molecular pharmacology of water movement - proposal of a new target for drug deisovery - .......... 22P

S13 Pharmacological approaches to elucidate the mechanisms for development of drug dependence/tolerance .......... 23P

S14 A role of pharmacology in drug discovery and the development process .......... 24P

S15 New strategies in medical research after completion of genome sequencing ....... 25P

S16 Frontiers in adrenomedullin research: from the cardiovascular to reproductive system .......... 26P

S17 Role of protein kinase C isozymes in cellular functions and pathological conditions - application to development of a new drug from a novel point of view - .......... 28P

S18 Molecular pharmacology of C^- channels: new targets fro drug discovery .......... 29P

S19 Neuronal and behavioral approaches for memory and learning .......... 30P

S20 New trends in seven-transmembrane-domain receptor research - dream of drug discovery - .......... 31P

S21 Potential influence of endocrine-disrupting chemicals on central nervous function .......... 34P

S22 Non-invasive approach for metabolic research: utilization of the stable isotope ¹³C .......... 35P

S23 Pharmacological and clinical significance of cytochrome P-450 .......... 36P

S24 Blood-brain barrier transport mechanism and drug delivery to the brain .......... 37P

S25 Genetic diseases and polymorphism of drug transporters .......... 39P

S26 Recent advances in the search for mu-opioid receptor function .......... 40P

S27 The role of pharmacology in therapeutics information .......... 41P

S28 The function of ATP in glial cells .......... 43P

S29 Clinical situation and pharmacology of pruritus .......... 44P

S30 Topics in the molecular biology of skeletal tissue pharmacology .......... 45P

S31 Development of oriental herbal remedies and pharmacological evidence supporting their current usage .......... 46P

S32 Newe vistas of cough pharmacology - mechanism and its application to new drug development - .......... 49P

S33 Role of pharmacological education for clinical trials - present status and perspecitves in Japan - .......... 49P

S34 Functional analysis of transport systems in parotid and submandibular gland cell membranes .......... 52P

S35 Molecular pharmacology of neuropathic pain .......... 53P

S36 The findings of new indications of a drug may overcome new drug discovery: cilostazol, as an example .......... 54P

S37 Brain organotypic slice culture as a potential tool for determination of neuroanl cell death and its protective drugs .......... 55P

S38 Clock gene and chronopharmacology: application to chronotherapeutics .......... 56P

Free Communications
Poster Sessions

Cardiovascular Pharmacology .......... P-1 - P-179
(Endothelium .......... P-1 - P-42)
(Cardiac Functions .......... P-43 - P-96)
(Vascular Smooth Muscles .......... P-97 - P-139)
(Blood Pressure and Circulation .......... P-140 - P-179)
Gastrointestinal Pharmacology .......... P-180 - P-220
Bone and dental Pharmacology .......... P-221 - P-237
Immunopharmacology and Inflammation .......... P-238 - P-287
Chemotherapy .......... P-288 - P-290
Toxicology .......... P-291 - P-305
Biogenic Active Substances .......... P-306 - P-334
Receptors and Channels .......... P-335 - P-432
Signal Transduction ..........P-433 - P-486
Biochemical Pharmacology .......... P-487 - P-509
Molecular Pharmacology .......... P-510 - P-524
Molecular Biology .......... P-525 - P-549
Respiratory Pharmacology ......... P-550 - P-569
Renal Pharmacology ......... P-570 - P-594
Endocrine Pharmacology .......... P-595 - P-612
Autonomic Nervous System Pharmacology .......... P-613 - P-627
Central Nervous System Pharmacology .......... P-628 - P-856
(Analgesia .......... P-628 - P-662)
(Dependence and Tolerance .......... P-663 - P-674)
(Neuropharmacology .......... P-675 - P-758)
(Behavioral Pharmacology .......... P-759 - P-792)
(Neurotransmitters .......... P-793 - P-809)
(Memory and Learning .......... P-810 - P-830)
(Neurochemistry ......... P-831 - P-856)
Neurotrophic Factors ......... P-857 - P-869
Smooth Muscle Pharmacology .......... P-870 - P-907
Clinical Pharmacology ......... P-908 - P-915

Author Index.
Subject Index

============================================================================================

Subscription/back issue orders: to Subscription Information